Form 4: MannKind Corp Executive Dominic Marasco Reports Acquisition of 252,000 Shares

Dominic Marasco, President of the Endocrine Business Unit at MannKind Corp, reports acquiring 252,000 shares of common stock on February 12, 2025.

Summary

• On February 12, 2025, Dominic Marasco, the President of the Endocrine Business Unit at MannKind Corp, acquired 252,000 shares of common stock.
• These shares were acquired as restricted stock units, each representing a contingent right to receive one share of MNKD common stock.
• The restricted stock units vest over a four-year schedule, with no shares vesting on the first anniversary of the vesting determination date of January 6, 2025, and one-third vesting on each subsequent anniversary until fully vested on the fourth anniversary.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing related to stock ownership. The acquisition of shares by an executive is generally viewed as a positive, but the document itself is simply a disclosure.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings of company insiders.

Key Dates

Keywords

Form 4, Beneficial Ownership, MNKD, MannKind Corp, Dominic Marasco, Restricted Stock Units, Vesting Schedule, Executive Compensation